Testing Immunotherapies in Syngeneic Models

Cancer immunotherapies are designed to work in conjunction with a patient's immune system to increase native anti-tumor responses. In this field of study, conventional xenograft models lack relevance due to the animals’ immunocompromised status. A syngeneic mouse model (e.g., 4T1 and MC38 cell lines), however, provides an effective approach for studying how cancer therapies perform in the presence of a functional immune system.

Charles River offers a broad range of syngeneic mouse models with well-characterized responses to known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1, anti-CTLA-4), immune profiling, and genetic evaluation (e.g., whole exome sequencing, RNA-seq). With a portfolio of syngeneic models that are responsive to immunotherapies as well complimentary in vitro and in vivo models in patient-derived xenografts (PDX), humanized models, and target validation, Charles River is your ideal partner to advance your immuno-oncology pipeline.

SYNGENEIC MODEL DATA
syngeneic mouse model, syngeneic model data

Access our syngeneic model data including check point inhibitor and whole exome sequencing (WES).

Download now

We offer models profiled for response with checkpoint inhibitors and/or chemotherapies.

  • SYNGENEIC MODELS WITH PROFILE
    Histotype Cell Line
    Bladder MBT-2
    Brain GL261
    Breast 4T1, EMT-6
    Colon Colon26, CT26, MC38
    Lung KLN 205, Lewis Lung, Madison109
    Lymphoma A20, E.G7-OVA
    Melanoma B16F10, CloudmanS91
    Pancreatic Pan02
    Renal Renca

We also offer models with growth curves, but no standard agent/checkpoint inhibitor data.

  • SYNGENEIC MODELS WITHOUT PROFILE*
    Histotype Cell Line
    Breast EMT-6-BRCA1(−/−), EMT-6-BRCA1(+/−), 4T1-BRCA1(+/−)
    Hepatoma Yoshida
    Leukemia C1498, L1210, P388
    Lymphoma EL4
    Mastocytoma P815
    Plasmacytoma J558
    Sarcoma EHS

    * Note: Although these models have not yet been profiled for response to current standards of care, tumor growth curve data is available.

Complementary Immunology Assays

As the science evolves, we have worked to enhance our portfolio with additional mouse models of cancer and will continue to expand into additional models that allow for this simulation in vitro and in vivo, including humanized models; genetically altered models; and cytokine response, T-cell activation, and toxicity assays.